2021 Year in Review - Renal-Cell Carcinoma

Over the past year, the COVID-19 pandemic has continued to affect the dissemination of critical clinical study findings. Read More ›

In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease. Read More ›

In a phase 3 trial, lenvatinib combined with pembrolizumab improved progression-free survival versus lenvatinib plus pembrolizumab or sunitinib and improved overall survival compared with sunitinib. Read More ›

In a phase 3 trial, nivolumab combined with cabozantinib improved progression-free survival and overall survival versus sunitinib as first-line therapy. Read More ›

Compared with sorafenib, tivozanib was associated with longer progression-free survival, higher rates of response, and better tolerability in the third-line setting and beyond. Read More ›

In a phase 1b/2 study, lenvatinib plus pembrolizumab combination showed promise as first-line therapy and beyond. Read More ›

In a phase 2 trial, atezolizumab plus bevacizumab showed promise after disease progression on monotherapy with atezolizumab or sunitinib. Read More ›

The hypoxia-inducible factor-2α inhibitor belzutifan had antitumor activity in treatment-naïve and pretreated disease. Read More ›

Combination therapy with cabozantinib and atezolizumab is associated with tolerability and antitumor activity across diverse renal-cell carcinoma histologies. Read More ›

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma. Read More ›